CO5570659A2 - Composiciones de valdecoxib de disgregacion intraoral - Google Patents

Composiciones de valdecoxib de disgregacion intraoral

Info

Publication number
CO5570659A2
CO5570659A2 CO04028410A CO04028410A CO5570659A2 CO 5570659 A2 CO5570659 A2 CO 5570659A2 CO 04028410 A CO04028410 A CO 04028410A CO 04028410 A CO04028410 A CO 04028410A CO 5570659 A2 CO5570659 A2 CO 5570659A2
Authority
CO
Colombia
Prior art keywords
composition
pharmaceutically acceptable
approximately
oral
valdecoxib
Prior art date
Application number
CO04028410A
Other languages
English (en)
Spanish (es)
Inventor
T Le Trang
C Ludwig Blake
Joseph P Reo
J Shah Uday
Yamamoto Ken
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of CO5570659A2 publication Critical patent/CO5570659A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO04028410A 2001-09-26 2004-03-26 Composiciones de valdecoxib de disgregacion intraoral CO5570659A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32535601P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
CO5570659A2 true CO5570659A2 (es) 2005-10-31

Family

ID=23267542

Family Applications (2)

Application Number Title Priority Date Filing Date
CO04028410A CO5570659A2 (es) 2001-09-26 2004-03-26 Composiciones de valdecoxib de disgregacion intraoral
CO04028409A CO5570684A2 (es) 2001-09-26 2004-03-26 Composiciones de disgregacion intraoral organolepticamente aceptables

Family Applications After (1)

Application Number Title Priority Date Filing Date
CO04028409A CO5570684A2 (es) 2001-09-26 2004-03-26 Composiciones de disgregacion intraoral organolepticamente aceptables

Country Status (25)

Country Link
US (1) US20030181501A1 (cg-RX-API-DMAC7.html)
EP (2) EP1429736A2 (cg-RX-API-DMAC7.html)
JP (2) JP2005512964A (cg-RX-API-DMAC7.html)
KR (2) KR20040058189A (cg-RX-API-DMAC7.html)
CN (2) CN1633281A (cg-RX-API-DMAC7.html)
AP (2) AP2004002999A0 (cg-RX-API-DMAC7.html)
AR (1) AR037239A1 (cg-RX-API-DMAC7.html)
BR (2) BR0212778A (cg-RX-API-DMAC7.html)
CA (2) CA2461630A1 (cg-RX-API-DMAC7.html)
CO (2) CO5570659A2 (cg-RX-API-DMAC7.html)
EA (2) EA200400357A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP045029A (cg-RX-API-DMAC7.html)
GE (1) GEP20063856B (cg-RX-API-DMAC7.html)
HK (1) HK1079988A1 (cg-RX-API-DMAC7.html)
IL (2) IL160855A0 (cg-RX-API-DMAC7.html)
IS (2) IS7178A (cg-RX-API-DMAC7.html)
MA (2) MA27682A1 (cg-RX-API-DMAC7.html)
MX (2) MXPA04002798A (cg-RX-API-DMAC7.html)
NO (2) NO20041258L (cg-RX-API-DMAC7.html)
OA (2) OA12707A (cg-RX-API-DMAC7.html)
PL (2) PL369298A1 (cg-RX-API-DMAC7.html)
TN (2) TNSN04045A1 (cg-RX-API-DMAC7.html)
WO (2) WO2003026623A1 (cg-RX-API-DMAC7.html)
YU (1) YU34804A (cg-RX-API-DMAC7.html)
ZA (2) ZA200401953B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050186271A1 (en) * 2004-02-24 2005-08-25 Sheskey Paul J. Process for dispersing a fluid in a mass of solid particles
KR20130018956A (ko) * 2004-08-10 2013-02-25 아지노모토 가부시키가이샤 쓴맛이 감소된 나테글리니드 함유 제제
JP5209876B2 (ja) * 2004-12-28 2013-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 速崩壊性錠剤及びその製造方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JPWO2007072840A1 (ja) * 2005-12-20 2009-05-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有する口腔内速崩錠
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US20090136570A1 (en) * 2006-01-20 2009-05-28 Bhagwant Rege Taste-Masked Tablets and Granules
US20070196494A1 (en) * 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
CA2687124A1 (en) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
EP2164460B1 (de) * 2007-06-06 2017-08-09 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
WO2008148742A2 (de) * 2007-06-06 2008-12-11 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
CN101686931B (zh) * 2007-06-06 2013-06-19 巴斯夫欧洲公司 用于制备可咀嚼片剂和锭剂的药物配制剂
JP5420535B2 (ja) * 2007-06-06 2014-02-19 ビーエーエスエフ ソシエタス・ヨーロピア 速崩性錠剤製造のための医薬製剤
DK2604257T3 (en) * 2007-08-07 2017-08-28 Acelrx Pharmaceuticals Inc ORAL TRANSMUCOSAL DOSAGE FORMS INCLUDING SUFENTANIL AND TRIAZOLAM
EP2268268A2 (en) * 2008-03-24 2011-01-05 Wockhardt Research Centre Orally disintegrating compositions of rhein or diacerein
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US20110229570A1 (en) * 2008-11-25 2011-09-22 Masaaki Sugimoto Orally rapidly disintegrating tablet and process for producing same
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
PE10898A1 (es) * 1995-06-13 1998-03-20 American Home Prod Formulaciones orales de etodolac s (+)-
DK0855988T3 (da) * 1995-10-20 2002-08-19 Upjohn Co Blisterpakning
EP0910368A1 (en) * 1996-05-17 1999-04-28 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
WO2001041761A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Valdecoxib compositions
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
NZ524124A (en) * 2000-08-18 2004-09-24 Pharmacia Corp Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物

Also Published As

Publication number Publication date
WO2003026697A3 (en) 2003-07-03
GEP20063856B (en) 2006-06-26
IL160848A0 (en) 2004-08-31
MXPA04002798A (es) 2004-07-05
PL369298A1 (en) 2005-04-18
EA200400357A1 (ru) 2004-08-26
CA2461044A1 (en) 2003-04-03
BR0212778A (pt) 2004-12-07
PL369297A1 (en) 2005-04-18
IS7177A (is) 2004-03-11
EA200400352A1 (ru) 2004-12-30
AP2004002998A0 (en) 2004-03-31
YU34804A (sh) 2006-08-17
KR20040058189A (ko) 2004-07-03
CO5570684A2 (es) 2005-10-31
AP2004002999A0 (en) 2004-03-31
AR037239A1 (es) 2004-11-03
ZA200401953B (en) 2005-05-09
TNSN04045A1 (fr) 2006-06-01
WO2003026623A8 (en) 2004-09-30
HK1079988A1 (zh) 2006-04-21
CN1633281A (zh) 2005-06-29
MA27542A1 (fr) 2005-10-03
ZA200402364B (en) 2005-01-13
OA13060A (en) 2006-11-10
JP2005512964A (ja) 2005-05-12
ECSP045029A (es) 2004-04-28
KR20040044990A (ko) 2004-05-31
BR0212861A (pt) 2004-10-05
IL160855A0 (en) 2004-08-31
CN1703203A (zh) 2005-11-30
CA2461630A1 (en) 2003-04-03
NO20041258L (no) 2003-03-27
MXPA04002652A (es) 2004-06-07
EP1429736A2 (en) 2004-06-23
IS7178A (is) 2004-03-11
MA27682A1 (fr) 2006-01-02
US20030181501A1 (en) 2003-09-25
OA12707A (en) 2006-06-26
WO2003026623A1 (en) 2003-04-03
NO20041532L (no) 2004-04-15
TNSN04047A1 (fr) 2006-06-01
EP1490035A1 (en) 2004-12-29
WO2003026697A2 (en) 2003-04-03
JP2005506987A (ja) 2005-03-10

Similar Documents

Publication Publication Date Title
CO5570659A2 (es) Composiciones de valdecoxib de disgregacion intraoral
MY142204A (en) Pramipexole once-daily dosage form
DE60121570D1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
US20020168404A1 (en) Use of an acrylic type polymer as disintegrating agent
AR012358A1 (es) Formulaciones de liberacion prolongada de derivados de eritromicina y su uso para la manufactura de un medicamento
SE8304393D0 (sv) Controlled release naproxen and naproxen sodium tablets
MX2009001711A (es) Formulaciones de liberacion sostenida de topiramato.
JP2005506987A5 (cg-RX-API-DMAC7.html)
FR2727016B1 (fr) Compositions pharmaceutiques a base d'ondansetron
CY1109636T1 (el) Συνθεση στοματικης δοσης παρατεταμενης απελευθερωσης
EA200000246A1 (ru) Быстро дезинтегрирующие таблетки метилцеллюлозы
CO5280073A1 (es) Composiciones
JP2005528430A5 (cg-RX-API-DMAC7.html)
AP2003002763A0 (en) Controlled release formulations for oral administration
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
Fei et al. Fracture resistance and stress distribution of repairing endodontically treated maxillary first premolars with severe non-carious cervical lesions
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
ES2148766T3 (es) Derivados de 10-desacetil-14beta-hidroxibaccatina iii, procedimiento para su preparacion y formulaciones que los contienen.
Messerli Evolution of calcium antagonists: past, present, and future
Haju et al. Buccal film: A novel approach for oral mucosal drug delivery system
MX9704043A (es) Surtido de farmaco de liberacion sostenida empleando una goma de hidrocoloide en polvo obtenible a partir de plantas superiores.
JP2019515045A (ja) 甲状腺ホルモン又はそのアナログを提供する組成物及び方法
EE05098B1 (et) Molsidomiini pikendatud vabanemisega oraalne galeeniline ravimvorm
ES2533584T3 (es) Formas de dosificación oral sólidas de dosis baja para TSH
Andersson-Wenckert et al. Interfacial adaptation of in vivo aged polyacid-modified resin composite (compomer) restorations in primary molars: A SEM evaluation

Legal Events

Date Code Title Description
FA Application withdrawn